AU2010319680B2 - Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells - Google Patents

Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells Download PDF

Info

Publication number
AU2010319680B2
AU2010319680B2 AU2010319680A AU2010319680A AU2010319680B2 AU 2010319680 B2 AU2010319680 B2 AU 2010319680B2 AU 2010319680 A AU2010319680 A AU 2010319680A AU 2010319680 A AU2010319680 A AU 2010319680A AU 2010319680 B2 AU2010319680 B2 AU 2010319680B2
Authority
AU
Australia
Prior art keywords
cells
grp
mammalian
div
cultured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010319680A
Other languages
English (en)
Other versions
AU2010319680A1 (en
Inventor
James T. Campanelli
Deborah A. Eppstein
Robert Sandrock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Q Therapeutics Inc
Original Assignee
Q Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q Therapeutics Inc filed Critical Q Therapeutics Inc
Publication of AU2010319680A1 publication Critical patent/AU2010319680A1/en
Application granted granted Critical
Publication of AU2010319680B2 publication Critical patent/AU2010319680B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
AU2010319680A 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells Ceased AU2010319680B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26044109P 2009-11-12 2009-11-12
US61/260,441 2009-11-12
US32679910P 2010-04-22 2010-04-22
US61/326,799 2010-04-22
PCT/US2010/055956 WO2011059952A1 (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Publications (2)

Publication Number Publication Date
AU2010319680A1 AU2010319680A1 (en) 2012-07-05
AU2010319680B2 true AU2010319680B2 (en) 2014-05-29

Family

ID=43991980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010319680A Ceased AU2010319680B2 (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Country Status (11)

Country Link
US (2) US10351823B2 (enExample)
EP (2) EP2499238B1 (enExample)
JP (2) JP5952737B2 (enExample)
CN (2) CN105602889A (enExample)
AU (1) AU2010319680B2 (enExample)
CA (1) CA2780541C (enExample)
DK (1) DK2499238T3 (enExample)
ES (1) ES2649396T3 (enExample)
NO (1) NO2499238T3 (enExample)
PL (1) PL2499238T3 (enExample)
WO (1) WO2011059952A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030223972A1 (en) 2002-02-15 2003-12-04 Goldman Steven A. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
WO2016049397A1 (en) * 2014-09-26 2016-03-31 The Procter & Gamble Company Freshening compositions and devices comprising same
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
EP3737751B1 (en) 2019-03-21 2026-08-12 Fornia BioSolutions, Inc. Additional phytase variants and methods
KR102322635B1 (ko) * 2021-06-11 2021-11-05 인제대학교 산학협력단 말초신경양 미세조직 제조방법 및 이의 용도
WO2023278783A1 (en) * 2021-06-30 2023-01-05 The Regents Of The University Of California Methods to generate glial restricted neural progenitor cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037222A1 (en) * 1997-07-04 2007-02-15 Rao Mahendra S Lineage restricted glial precursors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295197A1 (en) 1999-09-08 2001-03-08 Appleton Papers Inc. Thermally-responsive record material
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20050272149A1 (en) * 2004-06-02 2005-12-08 Life & Brain Gmbh Therapeutic delivery of adenosine into a tissue
US20090155223A1 (en) * 2007-08-14 2009-06-18 The Johns Hopkins University Cell-based compositions and methods for treating conditions of the nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037222A1 (en) * 1997-07-04 2007-02-15 Rao Mahendra S Lineage restricted glial precursors

Also Published As

Publication number Publication date
CA2780541C (en) 2015-07-14
WO2011059952A1 (en) 2011-05-19
ES2649396T3 (es) 2018-01-11
CN102686721A (zh) 2012-09-19
CN105602889A (zh) 2016-05-25
EP3269803A3 (en) 2018-04-25
NO2499238T3 (enExample) 2018-01-27
EP2499238A4 (en) 2013-10-02
JP5952737B2 (ja) 2016-07-13
US20120230963A1 (en) 2012-09-13
CA2780541A1 (en) 2011-05-19
PL2499238T3 (pl) 2018-04-30
HK1174953A1 (zh) 2013-06-21
JP2013510570A (ja) 2013-03-28
EP2499238A1 (en) 2012-09-19
EP2499238B1 (en) 2017-08-30
DK2499238T3 (en) 2017-12-04
JP6346629B2 (ja) 2018-06-20
AU2010319680A1 (en) 2012-07-05
US20190032010A1 (en) 2019-01-31
EP3269803A2 (en) 2018-01-17
CN102686721B (zh) 2016-02-10
US10351823B2 (en) 2019-07-16
JP2016146831A (ja) 2016-08-18

Similar Documents

Publication Publication Date Title
CA2780541C (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
Wang et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination
TWI586805B (zh) 獲得及維持在體外易於分化為寡樹突細胞－族系細胞之哺乳類神經幹細胞及／或神經祖源細胞的純或增富族群之培養方法
Sandner et al. Neural stem cells for spinal cord repair
CN103396993B (zh) 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞
Mothe et al. Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination
JP5816644B2 (ja) ヒト胚性幹細胞から、高収率で、神経前駆細胞、神経細胞及び機能性ドーパミン神経細胞を生成する方法
Wang et al. Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains
KR20230165846A (ko) 도파민성 전구세포 및 사용 방법
JP2004511266A (ja) 間葉間質細胞に対する治療的利用法
US20090136456A1 (en) Methods of treating neurodegenerative disorders
Abdanipour et al. Intraspinal transplantation of motoneuron-like cell combined with delivery of polymer-based glial cell line-derived neurotrophic factor for repair of spinal cord contusion injury
US20120202745A1 (en) Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
Liu et al. Characterization and therapeutic evaluation of a Nestin+ CNP+ NG2+ cell population on mouse spinal cord injury
Khanna et al. Generation and transplantation of dopaminergic neurons derived from embryonic stem cells
HK1174953B (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
JP2018501782A (ja) 運動ニューロン前駆細胞を持続的に成長させる方法及び医薬組成物
Canzi Human stem cells for the treatment of motorneuron diseases: regenerative potential, translatability and development of new biotechnologies. Cellule staminali umane per la cura delle malattie degenerative del motoneurone
Mead Mesenchymal stem cell therapy for traumatic and degenerative eye disease
HK1093219B (en) Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired